Home > Insider Trading > Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Inc. (ARWR)

Market is closed

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

News

First
<< Previous
11 - 20
Next >>

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2023 Earnings Call Transcript

Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. I will now hand the conference over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead.

Keep Reading →

May 4th, 2023 - News Transcripts

12 High Growth Healthcare Stocks to Buy

The healthcare sector proved its mettle in 2022.

Keep Reading →

February 26th, 2023 - Hedge Funds News

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2023 Earnings Call Transcript

Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. I will now hand the conference over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead.

Keep Reading →

February 8th, 2023 - News Transcripts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2022 Earnings Call Transcript

Operator: Ladies and gentlemen, welcome to Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode.

Keep Reading →

December 15th, 2022 - News Transcripts

Baron Funds Sold Arrowhead Pharmaceuticals (ARWR) to Reallocate to Higher Conviction Ideas

Baron Funds, an asset management company, released its “Baron Global Advantage Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here.

Keep Reading →

September 13th, 2022 - Hedge Fund Investor Letters News

Baron Funds: "We Retain Conviction in Arrowhead (ARWR)"

Baron Funds, an asset management firm, published its “Baron Opportunity Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.

Keep Reading →

June 14th, 2022 - Hedge Fund Investor Letters News

Top 5 Stock Picks of Frank Fu's CaaS Capital

In this article, we discuss the top 5 stock picks of Frank Fu's CaaS Capital.

Keep Reading →

June 7th, 2022 - Hedge Funds News

Should I Avoid Arrowhead Pharmaceuticals Inc. (ARWR)?

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September.

Keep Reading →

December 11th, 2021 - Hedge Funds News

Is it a Good Thing to Keep Your Arrowhead Pharmaceuticals (ARWR) Shares?

Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” third quarter 2021 investor letter – a copy of which can be downloaded here.

Keep Reading →

November 10th, 2021 - Hedge Fund Investor Letters News

Is Arrowhead Pharmaceuticals (ARWR) Still a Great Investment Pick?

Baron Funds, an asset management firm, published its “Baron Health Care Fund” third quarter 2021 investor letter – a copy of which can be downloaded here.

Keep Reading →

November 8th, 2021 - Hedge Fund Investor Letters News